European Union, Agreement with Pfizer-Biontech to obtain 1.8 billion doses of the vaccine “The European Union is working on a new contract with Pfizer-Biontech to obtain 1.8 billion doses for the period 2021-2023 of the covid-19 vaccine.” This was announced by European Commission President Ursula von der Leyen during the press conference with Pfizer CEO Albert Burla at the Bors plant, together with the Prime Minister of Belgium de Crewe.
At least 26 European Union countries have joined the European Commission’s decision to go ahead with legal proceedings against AstraZeneca. It was learned from several European diplomatic sources. The advisors’ decision was announced through the Steering Council mechanism (the committee that includes the commission and the capitals). Germany was among the last countries to give its approval. However, the sources were not in a position to confirm Hungary’s approval. In principle, however, the executive branch of society should proceed with legal proceedings. A decision is expected in this regard today.
The European Medicines Agency (EMA) has recommended that a second dose of AstraZeneca vaccine be continued between 4 and 12 weeks after the first is given, consistent with the product information. And so in the EMA note.
“The balance between benefits and risks of the AstraZeneca vaccine remains positive for adults in all age groups.” The EMA says in a note in which he notes that “the benefits of vaccination increase with age and infection rates.”
The European Medicines Agency (EMA) confirms in its new evaluation that the benefits of the AstraZeneca vaccine outweigh the risks, noting that “the national authorities are looking at other factors and how to best use the vaccines.”
Reproduction is reserved © Copyright ANSA